Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers

The authors evaluated the impact of a chronotherapy with 5-FU, folinic acid and carboplatine (chronomodulated infusions by ambulatory pumps; 5/21 days) for the management of oesophagus (52 cases) and gastric (56 cases) cancer patients. The overall tolerance of treatment was gauged excellent (grade 3...

Full description

Saved in:
Bibliographic Details
Published in:Pathologie biologie (Paris) 2007-04, Vol.55 (3-4), p.181-185
Main Authors: Focan, C, Kreutz, F, Longrée, L, Graas, M-P, Moeneclaey, N, Demolin, G, Focan-Henrard, D
Format: Article
Language:fre
Subjects:
Aged
Aged, 80 and over
Antibody Formation - drug effects
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Chronotherapy - methods
Drug Administration Schedule
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - physiopathology
Female
Humans
Leucovorin - administration & dosage
Male
Middle Aged
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Stomach Neoplasms - physiopathology
Survival Analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors evaluated the impact of a chronotherapy with 5-FU, folinic acid and carboplatine (chronomodulated infusions by ambulatory pumps; 5/21 days) for the management of oesophagus (52 cases) and gastric (56 cases) cancer patients. The overall tolerance of treatment was gauged excellent (grade 3-4; % patients: mucitis: 11-23%; leucopenia 6-19%; thrombopenia 18-50%; almost no digestive disturbances nor alopecia). Also tumor outcome was considered interesting with major responses rate in 61% (gastric) to 79% (oesophagus) of patients. The median survival of oesophageal cancer was limited to 9.2 months; the one of disseminated gastric cancer was 12.7 months but 72% of curatively resected patients were alive at 5+ years.
ISSN:0369-8114